Richard Stone, MD
Orlando, Fla.—Based on an overall survival (OS) benefit in a Phase III trial, midostaurin was declared a standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are positive for FLT3 mutations.
In the randomized study, the addition of midostaurin to commonly used induction and consolidation regimens followed by midostaurin maintenance provided an OS advantage over placebo that was consistent across all three activating FLT3 subtype